Compare LFMD & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | GALT |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | United States | United States |
| Employees | 336 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.6M | 199.2M |
| IPO Year | N/A | 2008 |
| Metric | LFMD | GALT |
|---|---|---|
| Price | $4.00 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $9.14 | $8.50 |
| AVG Volume (30 Days) | ★ 1.2M | 349.4K |
| Earning Date | 03-09-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.76 | N/A |
| Revenue Next Year | $17.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.60 | $1.15 |
| 52 Week High | $15.34 | $7.13 |
| Indicator | LFMD | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 44.18 |
| Support Level | $3.43 | $2.57 |
| Resistance Level | $4.20 | $3.37 |
| Average True Range (ATR) | 0.35 | 0.24 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 60.81 | 27.38 |
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.